Safety of healthy subjects in first-in-human multiple-dose studies: A pooled analysis

por Jung, David, Braun, Inka Valeska, Wensing, Georg
Publicado 2021

Pharmacodynamic Effects of an Angiotensin II Receptor-Antagonist in Phase I—Comparison between Healthy Subjects and Patients with Hypertension

por Wensing, Georg, Ochmann, Klaus, Boettcher, Michael, Schäfer, Anja, Kuhlmann, Jochen
Publicado 2007

Antiplatelet effects of aspirin are not affected by the soluble guanylate cyclase activator cinaciguat (BAY 58-2667)

por Frey, Reiner, Mueck, Wolfgang, Becka, Michael, Kraetzschmar, Joern, Wensing, Georg
Publicado 2011

Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)

por Frey, Reiner, Mück, Wolfgang, Kirschbaum, Nina, Krätzschmar, Jörn, Weimann, Gerrit, Wensing, Georg
Publicado 2009

Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment

por Frey, Reiner, Becker, Corina, Unger, Sigrun, Schmidt, Anja, Wensing, Georg, Mueck, Wolfgang
Publicado 2013

Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment

por Frey, Reiner, Becker, Corina, Unger, Sigrun, Schmidt, Anja, Wensing, Georg, Mueck, Wolfgang
Publicado 2013

Bioavailability, pharmacokinetics and safety of riociguat given as an oral suspension or crushed tablet with and without food

por Saleh, Soundos, Frey, Reiner, Becker, Corina, Unger, Sigrun, Wensing, Georg, Mück, Wolfgang
Publicado 2015

No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of riociguat (BAY 63-2521) and aspirin

por Frey, Reiner, Mück, Wolfgang, Unger, Sigrun, Reber, Michael, Krätzschmar, Jörn, Becker, Corina, Wensing, Georg
Publicado 2011

How to Interpret an Investigator’s Brochure for Meaningful Risk Assessment: Results of an AGAH Discussion Forum

por Rengelshausen, Jens, Breithaupt-Groegler, Kerstin, Donath, Frank, Erb-Zohar, Katharina, Hardman, Tim, Mikus, Gerd, Plassmann, Stephanie, Wensing, Georg, Sourgens, Hildegard
Publicado 2021

Acute hemodynamic response to single oral doses of BAY 60-4552, a soluble guanylate cyclase stimulator, in patients with biventricular heart failure

por Mitrovic, Veselin, Swidnicki, B, Ghofrani, Ardeschir, Mück, Wolfgang, Kirschbaum, Nina, Mittendorf, Joachim, Stasch, Johannes-Peter, Wensing, Georg, Frey, Reiner, Lentini, Silvia
Publicado 2009

Who is a ‘healthy subject’?—consensus results on pivotal eligibility criteria for clinical trials

por Breithaupt-Groegler, Kerstin, Coch, Christoph, Coenen, Martin, Donath, Frank, Erb-Zohar, Katharina, Francke, Klaus, Goehler, Karin, Iovino, Mario, Kammerer, Klaus Peter, Mikus, Gerd, Rengelshausen, Jens, Sourgens, Hildegard, Schinzel, Reinhard, Sudhop, Thomas, Wensing, Georg
Publicado 2017